Post hoc and exploratory analysis of the QuANTUM-First RCT in FLT3-ITD-positive AML receiving maintenance: without allo-HCT, quizartinib maintenance was associated with longer OS (HR 0.401); no OS benefit was shown in patients who had an allo-HCT.
Secondary analysis
Levis et al. Quizartinib for patients with newly diagnosed FLT3-ITD-positive AML who received maintenance therapy in QuANTUM-First